Alerts will be sent to your verified email
Verify EmailINDOCO
|
Indoco Remedies
|
Sakar Healthcare
|
Venus Remedies
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
54.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
32.0 . | n/a | n/a |
|
Domestic Sales Growth - YoY
|
4.0 % | n/a | n/a |
|
US DMF Filings
|
26.0 . | n/a | n/a |
|
Global DMFs filed
|
147.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
5.7 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
10.38 % | 8.14 % | 8.87 % |
|
5yr average Equity Multiplier
|
1.9 | 1.76 | 1.32 |
|
5yr Average Asset Turnover Ratio
|
0.88 | 0.45 | 0.96 |
|
5yr Avg Net Profit Margin
|
5.41 % | 10.03 % | 6.91 % |
|
Price to Book
|
2.07 | 5.73 | 2.71 |
|
P/E
|
0.0 | 60.99 | 18.13 |
|
5yr Avg Cash Conversion Cycle
|
35.3 Days | 18.72 Days | 46.96 Days |
|
Inventory Days
|
70.6 Days | 51.79 Days | 75.64 Days |
|
Days Receivable
|
83.16 Days | 53.06 Days | 54.28 Days |
|
Days Payable
|
111.01 Days | 115.64 Days | 58.86 Days |
|
5yr Average Interest Coverage Ratio
|
7.53 | 4.85 | 396.11 |
|
5yr Avg ROCE
|
13.6 % | 8.92 % | 8.42 % |
|
5yr Avg Operating Profit Margin
|
14.97 % | 24.94 % | 10.14 % |
|
5 yr average Debt to Equity
|
0.49 | 0.49 | 0.08 |
|
5yr CAGR Net Profit
|
n/a | 10.38 % | -6.01 % |
|
5yr Average Return on Assets
|
5.31 % | 4.54 % | 6.69 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
58.86 % | 52.86 % | 41.76 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.17 % | -7.86 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.36 % | 0.0 | 0.0 |
|
Indoco Remedies
|
Sakar Healthcare
|
Venus Remedies
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|